Howard Lewis Mcleod

Howard Lewis Mcleod's AcademicInfluence.com Rankings

Howard Lewis Mcleod

Biology

#5536

World Rank

#8042

Historical Rank

Computational Biology

#86

World Rank

#86

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Howard Lewis Mcleod Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Howard Lewis Mcleod's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacogenomics--drug disposition, drug targets, and side effects. (2003) (1696)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. (2005) (1407)
Doxorubicin pathways: pharmacodynamics and adverse effects (2011) (1073)
Genomics and drug response. (2011) (574)
Platinum neurotoxicity pharmacogenetics (2009) (495)
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. (2004) (487)
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. (2007) (469)
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs (2005) (455)
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. (2001) (436)
PI3K/Akt/mTOR pathway as a target for cancer therapy (2005) (425)
Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine (1998) (384)
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. (2002) (377)
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. (1999) (368)
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. (2008) (358)
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. (1996) (357)
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin (2003) (338)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (2018) (335)
CYP2D6 and tamoxifen: DNA matters in breast cancer (2009) (319)
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. (2017) (294)
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. (2002) (274)
Irinotecan pathway genotype analysis to predict pharmacokinetics. (2003) (270)
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. (2002) (270)
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype (2004) (253)
Strategies for enzyme/prodrug cancer therapy. (2001) (249)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB (2007) (249)
CpG island methylation of DNA damage response genes in advanced ovarian cancer. (2005) (248)
Thiopurine methyltransferase activity in American white subjects and black subjects (1994) (246)
Thiopurine methyltransferase alleles in British and Ghanaian populations. (1999) (243)
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. (2007) (237)
Tumour markers of prognosis in colorectal cancer (1999) (235)
A High-Resolution Map of Segmental DNA Copy Number Variation in the Mouse Genome (2006) (229)
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. (2009) (228)
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. (2002) (226)
Genomic Medicine: A Decade of Successes, Challenges, and Opportunities (2013) (224)
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations (2006) (224)
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. (1999) (220)
Contrasting patterns of Y chromosome and mtDNA variation in Africa: evidence for sex-biased demographic processes (2005) (217)
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. (2010) (216)
Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines (2003) (214)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (2018) (213)
Validation of Analytic Methods for Biomarkers Used in Drug Development (2008) (207)
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. (2017) (202)
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype (2005) (201)
Cancer pharmacogenetics: polymorphisms, pathways and beyond (2003) (200)
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. (2014) (198)
Known variant DPYD alleles do not explain DPD deficiency in cancer patients. (2000) (188)
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel (2005) (187)
Cytochrome P450 2C9-CYP2C9. (2010) (186)
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. (2009) (185)
Global implementation of genomic medicine: We are not alone (2015) (183)
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 (2012) (183)
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. (2011) (183)
Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. (2008) (178)
Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. (1999) (177)
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? (2001) (175)
Characterization of the human dihydropyrimidine dehydrogenase gene. (1998) (172)
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. (2008) (171)
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. (2001) (169)
β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome (2005) (166)
Laser capture microscopy (2000) (163)
Pharmacogenomics: Challenges and Opportunities (2006) (162)
Cancer pharmacogenomics: current and future applications. (2003) (156)
Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. (2004) (154)
ABCG2 Pharmacogenetics (2004) (151)
Genetic and clinical factors relating to warfarin dosing. (2009) (145)
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer (2001) (143)
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed (2013) (143)
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. (2004) (141)
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. (2006) (132)
Genetic basis of drug metabolism. (2002) (131)
Comparative genomic hybridization and chromosomal instability in solid tumours (1999) (127)
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. (2004) (126)
Pharmacogenomics (2019) (125)
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. (1998) (125)
Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia (1999) (125)
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. (1998) (123)
Novel thymidylate synthase enhancer region alleles in African populations (2000) (122)
Lessons learned from the irinotecan metabolic pathway. (2003) (120)
Pharmacogenomic assessment of carboxylesterases 1 and 2. (2004) (120)
PharmGKB summary: methotrexate pathway. (2011) (117)
Application of laser capture microdissection and proteomics in colon cancer (2001) (116)
Pharmacogenomic Discovery Using Cell-Based Models (2009) (114)
The kinetics and tissue distribution of protein transduction in mice. (2006) (113)
Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. (2001) (113)
Should DPD analysis be required prior to prescribing fluoropyrimidines? (2007) (111)
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. (2009) (107)
Distribution of ITPA P32T alleles in multiple world populations (2004) (107)
ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy (2008) (104)
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. (2013) (104)
Nomenclature for alleles of the thiopurine methyltransferase gene (2013) (102)
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway (2004) (98)
Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts (2004) (96)
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. (1998) (95)
The pharmacogenetics of coumarin therapy. (2005) (95)
A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303 (2011) (94)
Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. (1999) (93)
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects (2018) (93)
Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research (2017) (92)
Nomenclature for human DPYD alleles. (1998) (92)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy (2019) (91)
Copy number variants in pharmacogenetic genes. (2011) (91)
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (2004) (89)
PharmGKB summary: fluoropyrimidine pathways. (2010) (89)
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel (2012) (87)
Pharmacogenomics, ancestry and clinical decision making for global populations (2013) (87)
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. (2007) (86)
Analysis of key cell‐cycle checkpoint proteins in colorectal tumours (2002) (86)
Strategies for integrating personalized medicine into healthcare practice. (2017) (86)
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. (2005) (84)
Pharmacogenetics of irinotecan toxicity. (2004) (84)
Pharmacogenomics: from bedside to clinical practice. (2006) (82)
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? (2000) (82)
CYP3A4 and CYP3A5 genotyping by Pyrosequencing (2005) (82)
CANDID: a flexible method for prioritizing candidate genes for complex human traits (2008) (81)
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. (2012) (81)
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer (1994) (81)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (2010) (80)
Implementation of a pharmacogenomics service in a community pharmacy. (2014) (79)
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes (2008) (79)
ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition (2004) (78)
Tamoxifen and CYP2D6: a contradiction of data. (2012) (78)
CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1 (2004) (77)
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? (2003) (77)
c-erbB-2 is not a major factor in the development of colorectal cancer (2002) (76)
When will clinical trials finally reflect diversity? (2018) (75)
Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. (2012) (75)
Effect of grapefruit juice intake on etoposide bioavailability (2002) (74)
Thiopurine pathway. (2010) (74)
SNP databases and pharmacogenetics: great start, but a long way to go (2002) (74)
Clinically relevant drug-drug interactions in oncology. (1998) (73)
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. (2009) (72)
Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. (1998) (72)
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. (2017) (70)
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes (2003) (70)
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. (1996) (69)
Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines? (2008) (69)
Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient (2003) (67)
Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers (2014) (67)
Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer (2005) (66)
Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis (2006) (66)
High‐dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies (1994) (66)
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. (1999) (65)
Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. (2001) (64)
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia (2003) (63)
Economic opportunities and challenges for pharmacogenomics. (2010) (62)
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer (2005) (61)
NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. (2019) (61)
pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013 (2003) (60)
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies (2010) (60)
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. (2009) (60)
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. (2011) (59)
Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. (2013) (59)
Creating and evaluating genetic tests predictive of drug response (2008) (59)
Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes (2008) (59)
Exome Resequencing Identifies Potential Tumor‐Suppressor Genes that Predispose to Colorectal Cancer (2013) (58)
CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. (2002) (58)
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway (2016) (57)
Exploring the Distribution of Genetic Markers of Pharmacogenomics Relevance in Brazilian and Mexican Populations (2014) (57)
CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY (2005) (57)
miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer (2017) (56)
Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. (2000) (56)
Colorectal cancer genomics: evidence for multiple genotypes which influence survival (2001) (55)
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. (2005) (55)
Somatic cancer variant curation and harmonization through consensus minimum variant level data (2016) (55)
Defining the opportunity for pharmacogenetic intervention in primary care. (2006) (55)
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. (2005) (54)
Oral fluoropyrimidines in the treatment of colorectal cancer. (2000) (54)
Pharmacogenomic genome-wide association studies: lessons learned thus far. (2009) (54)
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (2004) (54)
Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer (2002) (53)
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. (1999) (53)
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer (2005) (53)
Dose and time dependencies of 5‐fluorouracil pharmacokinetics (2000) (52)
The candidate oncogene ZNF217 is frequently amplified in colon cancer (2004) (52)
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. (2012) (52)
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity (2013) (51)
Novel human CYP2A6 alleles confound gene deletion analysis (2004) (51)
A Novel Duplication Type of CYP2A6 Gene in African-American Population (2007) (50)
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. (2006) (50)
Autoregulation of 5-fluorouracil metabolism. (1998) (49)
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. (2000) (49)
Opportunities, resources, and techniques for implementing genomics in clinical care (2019) (49)
Pharmacogenomic discovery approaches: will the real genes please stand up? (2005) (48)
Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. (2005) (48)
Characterizing genetic variants for clinical action (2014) (48)
Comprehensive Evaluation of Carboxylesterase-2 Expression in Normal Human Tissues Using Tissue Array Analysis (2002) (48)
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. (2011) (47)
Irinotecan pharmacogenetics: is it time to intervene? (2004) (47)
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer (2011) (47)
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation (2010) (47)
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin (1994) (46)
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. (1996) (46)
Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks (2007) (45)
Genetic Variation in the B-Type Natiuretic Peptide Pathway Affects BNP Levels (2007) (45)
Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. (2004) (45)
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. (2016) (44)
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. (2010) (44)
Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer (2018) (44)
Systems pharmacology assessment of the 5-fluorouracil pathway. (2011) (44)
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients (2009) (43)
Platinum pathway. (2009) (43)
Pharmacogenetics and oncology treatment for breast cancer (2007) (43)
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes (2006) (42)
PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis (2005) (42)
Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. (2004) (42)
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy (2016) (42)
Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. (2005) (42)
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application (2011) (42)
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. (2004) (41)
Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. (2004) (41)
Evaluation of the linearity of docetaxel pharmacokinetics (1998) (41)
Using germline genotype in cancer pharmacogenetic studies. (2009) (40)
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy (2014) (40)
Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. (2000) (40)
Pharmacogenetic analysis of clinically relevant genetic polymorphisms. (2003) (40)
UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. (2006) (40)
Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. (2004) (40)
Pharmacogenetics: using DNA to optimize drug therapy. (2007) (39)
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. (1998) (39)
Therapeutic opportunities from tumour biology in metastatic colon cancer. (2000) (39)
Pharmacogenetics: ethical problems and solutions (2004) (38)
Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. (2007) (38)
Pharmacogenetics: more than skin deep (2001) (38)
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. (2013) (38)
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. (2015) (38)
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. (2014) (37)
Interethnic variability in human drug responses. (2001) (37)
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. (2000) (37)
DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer (2006) (37)
Making pharmacogenetic testing a reality in a community pharmacy. (2012) (37)
Pharmacogenomics: the influence of genomic variation on drug response. (2004) (37)
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. (2003) (36)
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. (2012) (36)
Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. (2002) (36)
The pharmacogenetics of antiretroviral therapy: a review of studies to date. (2004) (36)
Etoposide pathway. (2009) (36)
Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. (2003) (35)
Medical Genetics Summaries (2012) (35)
ANTIPSYCHOTIC-INDUCED VACUOUS CHEWING MOVEMENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS ARE HIGHLY HERITABLE IN MICE (2010) (35)
PromoLign: A database for upstream region analysis and SNPs (2004) (35)
Personalizing medicine in geriatric oncology. (2014) (34)
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. (2000) (34)
Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034 (2001) (34)
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. (2019) (34)
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT (2012) (33)
Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) (2014) (33)
Chemotherapy-induced tumor gene expression changes in human breast cancers (2009) (33)
Identification of NR1I2 genetic variation using resequencing (2007) (33)
Pharmacogenomics in a community pharmacy: ACT now. (2011) (33)
Therapeutic drug monitoring opportunities in cancer therapy. (1997) (33)
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data (2008) (33)
The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers (2014) (32)
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. (2002) (32)
Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice (2012) (32)
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer (2018) (32)
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. (2008) (32)
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. (1996) (31)
Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. (1997) (31)
Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. (2012) (31)
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance) (2015) (31)
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. (2002) (30)
A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report (2006) (30)
Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity (2005) (30)
Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3′-Untranslated Region Affect the Regulation of CYP2E1 by miR-570 (2015) (30)
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. (2013) (29)
Can pharmacogenomics improve malaria drug policy? (2011) (29)
Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: North Central Cancer Treatment Group (N0044) (2007) (29)
Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? (1994) (28)
Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. (2000) (28)
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. (2012) (28)
Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity (2013) (27)
Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. (2003) (27)
Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes (2018) (27)
Global pharmacogenetics: giving the genome to the masses. (2006) (27)
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar (2005) (27)
Current pharmacogenomic studies on hERG potassium channels. (2013) (27)
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). (2013) (27)
A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer (2005) (26)
The pharmacogenomics of drug resistance to protein kinase inhibitors. (2016) (26)
Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer (2017) (26)
Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas. (2005) (26)
Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. (2008) (26)
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. (2003) (26)
Pharmacogenomics of cancer chemotherapy-induced toxicity. (2007) (26)
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations (2015) (26)
Characterization of the topoisomerase I locus in human colorectal cancer. (2000) (26)
MAGED2: a novel p53-dissociator. (2007) (26)
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. (2012) (25)
Cloning and initial characterization of the human DPYD gene promoter. (2000) (25)
Clopidogrel pharmacogenetics: promising steps towards patient care? (2006) (25)
Genome-wide association studies: powerful tools for improving drug safety and efficacy. (2009) (25)
PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics (2015) (25)
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele (2006) (25)
ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer (2006) (25)
Pharmacogenetics of catechol‐O‐methyltransferase: Frequency of low activity allele in a Ghanaian population (2000) (25)
The Geographic Distribution of Monoamine Oxidase Haplotypes Supports a Bottleneck During the Dispersion of Modern Humans from Africa (2001) (25)
Aromatase Gene Polymorphisms Are Associated with Survival among Patients with Cardiovascular Disease in a Sex-Specific Manner (2010) (25)
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. (2003) (25)
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer (2001) (25)
Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. (1996) (24)
Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. (2013) (24)
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells (2013) (24)
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes (2018) (24)
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians (2013) (24)
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. (2008) (24)
High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. (1997) (24)
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. (2008) (23)
Implications of genome-wide association studies in cancer therapeutics. (2013) (23)
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. (2011) (23)
Vascular endothelial growth factor pathway. (2010) (23)
Primary pulmonary osteosarcoma (2001) (23)
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. (2005) (23)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (2018) (23)
Cancer clinical pharmacology (2005) (23)
Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. (2017) (23)
Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer. (2015) (22)
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. (2014) (22)
Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. (2008) (22)
Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. (2002) (22)
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. (2009) (22)
Applying the genome to national drug formulary policy in the developing world. (2010) (21)
Taxane pathway. (2009) (21)
Methylation of the DPYD Promoter and Dihydropyrimidine Dehydrogenase Deficiency (2006) (21)
UGT1A and irinotecan toxicity: keeping it in the family. (2009) (21)
Value of Supportive Care Pharmacogenomics in Oncology Practice. (2018) (21)
Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. (2004) (21)
Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). (2004) (21)
Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology (2014) (21)
A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes (2010) (20)
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. (1996) (20)
Prospective CYP2C19‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations (2020) (20)
Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. (2010) (20)
Polymorphism discovery in 51 chemotherapy pathway genes. (2005) (20)
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity (2009) (20)
A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care (2009) (19)
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks (2000) (19)
Will we ever be ready for blood level-guided therapy? (2008) (19)
The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A Historical Perspective (2006) (19)
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. (1999) (19)
Individualized cancer therapy: molecular approaches to the prediction of tumor response (2002) (19)
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients (2004) (19)
Clinical implementation of pharmacogenetics (2016) (19)
A mouse model for developing treatment for secondary liver tumors. (2005) (19)
Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. (2020) (19)
Association of Eleven Common, Low-Penetrance Colorectal Cancer Susceptibility Genetic Variants at Six Risk Loci with Clinical Outcome (2012) (18)
Genotype-guided neoadjuvant therapy for rectal cancer (2005) (18)
Analysis of uracil DNA glycosylase in human colorectal cancer. (2001) (18)
Pharmacogenetics and rational drug use around the world. (2011) (18)
Multivariate methods and software for association mapping in dose‐response genome‐wide association studies (2012) (18)
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists? (2013) (17)
Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. (2000) (17)
Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. (2010) (17)
Pharm.D. Pathways to Biomedical Research: The National Institutes of Health Special Conference on Pharmacy Research (2008) (17)
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. (2003) (17)
Comparison of 5‐Fluorouracil Pharmacokinetics in Whole Blood, Plasma, and Red Blood Cells in Patients with Colorectal Cancer (1997) (17)
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients (2018) (17)
Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. (2004) (16)
Drug pathways: moving beyond single gene pharmacogenetics. (2004) (16)
Pharmacogenomic assessment of Mexican and Peruvian populations. (2015) (16)
A Comparison of Association Methods for Cytotoxicity Mapping in Pharmacogenomics (2011) (16)
Gastric cancer pharmacogenetics: progress or old tripe? (2013) (16)
Challenges of implementing pharmacogenetics in the critical care environment (2004) (15)
Pharmacogenomic Contribution to Drug Response (2011) (15)
Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. (2003) (15)
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups. (2015) (15)
β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms. (2018) (15)
Using genome-wide mapping in the mouse to identify genes that influence drug response. (2003) (15)
Identification and Replication of Loci Involved in Camptothecin-Induced Cytotoxicity Using CEPH Pedigrees (2011) (15)
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors (2005) (15)
CEPH individuals are representative of the European American population: implications for pharmacogenetics. (2005) (15)
NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. (2009) (14)
Modeling the cost of immune checkpoint inhibitor-related toxicities. (2016) (14)
Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study (2020) (14)
Clinically relevant cancer biomarkers and pharmacogenetic assays (2014) (14)
Molecular predictors of prognosis and response to therapy in colorectal cancer. (2003) (14)
Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. (2006) (14)
Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors (2018) (14)
Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis (2018) (14)
Pharmacogenetics of breast cancer therapies. (2009) (14)
Pharmacogenetics goes 3D (2005) (14)
EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. (2017) (14)
Now's the time to find biomarkers on purpose. (2010) (14)
New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival (2006) (13)
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer (2009) (13)
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. (2009) (13)
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance) (2018) (13)
Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. (2009) (13)
Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML. (2015) (13)
High-throughput Genotyping Methods for Pharmacogenomic Studies (2004) (13)
Stability of etoposide solution for oral use. (1992) (13)
Pyrosequencing of clinically relevant polymorphisms. (2005) (13)
Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. (2004) (13)
Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. (2006) (13)
Propranolol suppresses the growth of colorectal cancer through simultaneously activating autologous CD8+ T cells and inhibiting tumor AKT/MAPK pathway. (2020) (13)
Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse (1998) (12)
Genetic strategies to individualize supportive care. (2002) (12)
Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial (2017) (12)
Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017 (2018) (12)
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. (2022) (12)
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. (2004) (12)
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment (2017) (12)
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer (2021) (12)
Selection of markers to predict tumour response or survival: description of a novel approach. (1999) (12)
The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. (2016) (12)
Cancer pharmacogenomics, adoption by oncologists and patient benefit. (2014) (12)
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. (2008) (12)
Race does not explain genetic heterogeneity in pharmacogenomic pathways. (2008) (11)
Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. (2012) (11)
Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines (2011) (11)
2-Adrenergic Receptor Genotype and Survival Among Patients Receiving -Blocker Therapy After an Acute Coronary Syndrome (2005) (11)
Assessing the utility of whole genome amplified DNA as a template for DMET Plus array (2012) (11)
Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. (2002) (11)
Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia (2004) (11)
Is it possible to design a logical development plan for an anti-cancer drug? (1995) (11)
Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory Guidance (2011) (11)
Validation of Analytical Methods for Biomarkers Employed in Drug Development (2009) (11)
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation (2018) (11)
The pharmacogenetics of medications used in general anesthesia. (2018) (11)
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial (2015) (11)
RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer (2004) (11)
Recent advances in the pharmacogenetics of cancer chemotherapy. (2002) (11)
Pharmacogenetics of alkylator-associated acute myeloid leukemia. (2006) (11)
Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat (2017) (11)
Primum non nocere: adverse drug events must be taken seriously. (2007) (11)
Pharmacogenetics and Pediatric Cancer (2005) (10)
Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. (2017) (10)
Using genetic variation to optimize cancer chemotherapy. (2003) (10)
Genetic variation determines VEGF-A plasma levels in cancer patients (2018) (10)
Epigenetic perspectives on cancer chemotherapy response. (2014) (10)
Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. (2008) (10)
Genomics: applications in mechanism elucidation. (2009) (10)
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib. (2010) (9)
Analysis of variation in mouse TPMT genotype, expression and activity. (2004) (9)
Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. (2018) (9)
A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure (2016) (9)
Use of pharmacogenetics to guide warfarin therapy. (2004) (9)
Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design? (2004) (9)
Genomewide Analysis of Inherited Variation Associated with Phosphorylation of PI3K/AKT/mTOR Signaling Proteins (2011) (9)
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. (2007) (9)
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) (2018) (9)
The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer (2018) (9)
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. (2009) (8)
A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study (2004) (8)
A Mixture Model Approach in Gene–Gene and Gene–Environmental Interactions for Binary Phenotypes (2008) (8)
Stability of Cyclosporine in Dextrose 5%, NaCl 0.9%, Dextrose/Amino Acid Solution, and Lipid Emulsion (1992) (8)
Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics (2007) (8)
PON1 Q192R and Clopidogrel: A Case of the Winner's Curse or Inadequate Replication? (2011) (8)
Beta2-adrenergic receptor genotype predicts survival: implications and future directions. (2006) (8)
Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. (2020) (8)
Geographic variation in molecular subtype for gastric adenocarcinoma (2018) (8)
Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity (2008) (8)
Polymorphism of the Thymidylate Synthase Gene and Thymidylate Synthase Levels in Colon Cancer Cell Lines and Different Tissues of Colorectal Cancer Patients (2004) (8)
Pharmacokinetics for the prescriber (2003) (8)
Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. (2015) (7)
Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model. (2004) (7)
McLeod et al. reply: Pyrimidine metabolism has a role in normal physiology as well as in regulating drug effects (1996) (7)
Pharmacokinetic Study of Infusional Valspodar (2002) (7)
Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection? (2006) (7)
Pharmacogenetic analysis of clinically relevant genetic polymorphisms. (2005) (7)
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. (2008) (7)
Pharmacokinetics after endovascular lung perfusion with Cisplatin. (2006) (7)
Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy. (2015) (7)
Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer (2014) (7)
Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia (2004) (7)
Differentially expressed genes in human peripheral blood as potential markers for statin response (2012) (7)
RNA expression of the molecular signature genes for metastasis in colorectal cancer. (2011) (7)
Genomic Medicine Year in Review: 2019. (2019) (7)
EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose. (2008) (6)
DNA methylotype analysis in colorectal cancer. (2008) (6)
Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter? (2007) (6)
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance) (2019) (6)
American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data. (2017) (6)
Irinotecan Therapy and UGT1A1 Genotype -- Medical Genetics Summaries (2012) (6)
Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial (2021) (6)
PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. (2022) (6)
Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure? (2004) (6)
Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups (2001) (6)
COMMENT ON “A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE” (2005) (6)
Pharmacogenetics [7] (multiple letters) (2003) (6)
Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis (2010) (6)
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). (2015) (6)
Ex-Vivo Modeling for Heritability Assessment and Genetic Mapping in Pharmacogenomics. (2011) (6)
Azathioprine Therapy and TPMT Genotype -- Medical Genetics Summaries (2012) (5)
Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure (2006) (5)
Strategies for Enzyme / Prodrug Cancer Therapy 1 (2001) (5)
Comparison of mRNA Expression Levels Determined with TAQ–Man and Competitive Template RT–PCR (2004) (5)
CHARACTERIZATION OF NOVEL CYP 2 A 6 POLYMORPHIC ALLELES ( CYP 2 A 6 * 18 AND CYP 2 A 6 * 19 ) THAT AFFECT ENZYMATIC ACTIVITY (2005) (5)
Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity (2004) (5)
The need to shift pharmacogenetic research from candidate gene to genome-wide association studies. (2021) (5)
Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. (2017) (5)
The Future of Radiation Oncology in Soft Tissue Sarcoma (2018) (5)
Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer (2021) (5)
Comment on: UGTA1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters (2008) (5)
Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity (2014) (5)
MAGED 2 : A novel p 53-dissociator (5)
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment (2021) (5)
miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer (2017) (4)
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype (2022) (4)
Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. (2021) (4)
Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off‐Label Drug Use (2017) (4)
Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML. (2007) (4)
Warfarin Therapy and VKORC1 and CYP Genotype -- Medical Genetics Summaries (2012) (4)
Caution with β1‐adrenergic receptor genotyping (2004) (4)
Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy. (2019) (4)
Enabling pharmacogenomic clinical trials through sampling. (2010) (4)
Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. (2016) (4)
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (4)
Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies (2004) (4)
Chapter 6 – Pharmacogenetics and Pharmacogenomics (2017) (4)
Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203 (2008) (4)
The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer. (2017) (4)
Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics (2014) (4)
Modeling the response of colorectal cancer (CRC) to common chemotherapy using multivariate gene expression. (2004) (3)
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. (2010) (3)
Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer (2014) (3)
Incorporating Molecular Oncology into Prognosis (2006) (3)
Pharmacogenetic analysis of paclitaxel in breast cancer (2005) (3)
Systems pharmacogenomics in yeast. (2006) (3)
Metoprolol Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (3)
Concordance of phenotype and genotype for CYP2D6 (1994) (3)
Pharmacokinetics: what you need to know (2006) (3)
Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines (2019) (3)
Atomoxetine Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (3)
Nevirapine hypersensitivity reaction: will the real HLA please stand up? (2009) (3)
Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers (2016) (3)
Clinical and pharmacogenetics associated with recovery time from general anesthesia. (2018) (3)
Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans (2004) (3)
Investigating the utilization of pharmacokinetic-guided fluorouracil in colorectal cancer. (2012) (3)
Race and responsiveness to drugs for heart failure. (2001) (3)
Found in translation: annals of oncology and translational research. (2011) (3)
Graying anatomy? Toward molecular tumor characterization. (2007) (3)
High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients. (2020) (3)
Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization. (2015) (3)
Capecitabine Therapy and DPYD Genotype -- Medical Genetics Summaries (2012) (3)
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. (2010) (3)
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) (2020) (3)
Single-Nucleotide Polymorphisms in Cytochrome P 450 2 E 1 ( CYP 2 E 1 ) 3 9-Untranslated Region Affect the Regulation of CYP 2 E 1 by miR-570 (2015) (3)
Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals (2021) (3)
Small inhibitory RNA--a tool for credentialing candidate genes. (2005) (3)
Metabolism of azathioprine. (1996) (3)
Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. (2012) (3)
Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice. (2013) (3)
Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy? (2000) (2)
Deutetrabenazine Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (2)
Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors (2017) (2)
UGT1A1 genotype-based dose modification of irinotecan regimens: Impact on hematologic toxicities (2008) (2)
Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics (2014) (2)
Applications of genomic tools to colorectal cancer therapeutics. (2008) (2)
Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance (2017) (2)
Title Identification of a Genomic Region between SLC 29 A 1 and HSP 90 AB 1 Associated with Risk of Bevacizumab-Induced Hypertension : CALGB 80405 ( Alliance ) (2018) (2)
Patients' Understanding of a CYP2D6 Tamoxifen Genotyping Study. (2009) (2)
Ethnicity and Pharmacogenomics (2003) (2)
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer (2019) (2)
Individualizing cancer chemotherapy. (2006) (2)
The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy (2011) (2)
Caution with beta1-adrenergic receptor genotyping. (2004) (2)
Genome-Wide Meta-Analysis Identifies a S1PR1 Genomic Region Associated with Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy (2020) (2)
ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC). (2019) (2)
Tramadol Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (2)
Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors (2020) (2)
β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer (2021) (2)
Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines (2022) (2)
Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer. (2005) (2)
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population. (2009) (2)
CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers. (2004) (2)
Potential germline relevance of tumor testing and the need for genetic referral. (2015) (2)
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance) (2021) (2)
5-Fluorouracil metabolizing enzymes. (1999) (2)
Title Comprehensive evaluation of variability in nicotine metabolism andCYP 2 A 6 polymorphic alleles in four ethnic populations (2017) (2)
Marked differences in tumour-associated protein expression and genetic stability between proximal and distal colon tumours (2001) (2)
Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. (2019) (2)
β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer (2021) (2)
Comparison of incidence and average cost per toxicity in patients treated with nivolumab and pembrolizumab. (2017) (1)
Association of copy number variants in colorectal liver metastases with 5-fluorouracil resistance. (2016) (1)
Current overview of pharmacogenetics. (2004) (1)
Gene expression profiling to predict recurrent Dukes' B colon cancer. (2004) (1)
Conference Scene: Is personalized medicine ready for prime time? (2012) (1)
Irinotecan pharmacogenetics: The influence of pharmacodynamic genes (2006) (1)
Incidence and risk factors for ibrutinib associated atrial fibrillation. (2016) (1)
S18 Pharmacogenetics to drive breast cancer treatments (2009) (1)
DPYD Testing: Time to Put Patient Safety First. (2023) (1)
The NQO 1 * 2 / * 2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer (1)
Using patient DNA to optimize therapy in heart failure patients: a move toward perfection (2010) (1)
Esomeprazole Therapy and CYP2C19 Genotype -- Medical Genetics Summaries (2012) (1)
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance). (2013) (1)
Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies. (2004) (1)
Drug pathways: one gene is not enough. (2007) (1)
Population pharmacokinetics of etoposide. (2002) (1)
Effect of race on cyclophosphamide (CP) metabolism. (2010) (1)
High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs (2021) (1)
Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races. (2011) (1)
Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population. (2016) (1)
Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG 2034 1 (2000) (1)
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. (2015) (1)
Heritage-specific mechanisms for cancer adverse reactions: one gene does not explain the world. (2015) (1)
Influence of glutathione S-transferase A1 genotype on intravenous busulfan pharmacokinetics (2008) (1)
Abstract PD07-10: Breast Cancer Patients Carrying the CYP2C8*3 Variant Are More Likely To Achieve Clinical Complete Response from Neoadjuvant Paclitaxel Treatment (2010) (1)
Economic benefits of adaptive abiraterone therapy for advanced prostate cancer. (2019) (1)
A Genomic Framework for Precision Radiation Therapy (2016) (1)
CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers (2004) (1)
TYMS genotype-directed neoadjuvant chemoradiation for rectal cancer. (2009) (1)
Clobazam Therapy and CYP2C19 Genotype -- Medical Genetics Summaries (2012) (1)
Propranolol suppresses bladder cancer by manipulating intracellular pH via NHE1 (2021) (1)
Clarity Also Needed for Direct-to-Consumer Pharmacogenetic Tests. (2019) (1)
Post-Genomic Technologies (2007) (1)
Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. (2019) (1)
A top‐down, step up approach to pharmacogenetic discovery using CEPH family cell lines (2005) (1)
Abstract PD10-07: Patients carrying CYP2C8*3 are at increased risk of paclitaxel-induced neuropathy (2012) (1)
Mercaptopurine Therapy and TPMT Genotype -- Medical Genetics Summaries (2012) (1)
Effect of genetic variants in CYP2C8, CYP3A4, CYP3A5, and ABCB1 on paclitaxel pharmacokinetics (2005) (1)
Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice (2011) (1)
Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity (2015) (1)
The influence of Neanderthal alleles on cytotoxic response (2018) (1)
Comparison of mRNA Expression Levels Determined with TAQ—Man and Competitive Template RT—PCR (2005) (1)
Tumor genomics and proteomics and drug pharmacokinetics in predicting chemotherapy response in breast cancer (2005) (1)
Celecoxib Therapy and CYP2C9 Genotype -- Medical Genetics Summaries (2012) (1)
A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study. (2004) (1)
Pharmacokinetic differences between ethnic groups. Authors' reply (2002) (1)
A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma (2022) (1)
Multivariate methods and software for association mapping in dose‐response genome‐wide association studies (2012) (1)
Genetic markers associated with platinum/taxanesinduced gastrointestinal toxicity in SCOTROC1trial (2011) (1)
Dissecting the role of cell signaling versus CD8+ T cell modulation in propranolol antitumor activity (2022) (1)
Prasugrel Therapy and CYP Genotype -- Medical Genetics Summaries (2012) (1)
2009 SSO Annual Cancer Symposium (2009) (0)
ACHOO Syndrome -- Medical Genetics Summaries (2012) (0)
Compound genotypes associated with beta-blocker efficacy in congestive heart failure are common (2004) (0)
801-4 High risk genotypes for myocardial infarction are more common in African Americans than European Americans (2004) (0)
Use of tumor gene expression signatures and drug-induced changes to discriminate early response in human breast cancer (2016) (0)
Assessment of a clinical and genetic algorithm to predict endoxifen concentration. (2016) (0)
12 – IMPROVING THE EFFICACY AND SAFETY OF ANTICANCER AGENTS — THE ROLE OF PHARMACOGENETICS (2006) (0)
Carisoprodol Therapy and CYP2C19 Genotype -- Medical Genetics Summaries (2012) (0)
Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD) (2016) (0)
Abstract 3226: Facilitating personalized medicine with cloud-based storage and analytics (2020) (0)
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). (2014) (0)
Thioridazine Therapy and CYP2D6 Genotypes -- Medical Genetics Summaries (2012) (0)
Level of burden of supportive care-relevant pharmacogenetic markers in general population. (2017) (0)
Expression of Cell Cycle Control Proteins in Primary Colorectal Tumors Does Not Always Predict Expression in Lymph Node Metastases 1 (2000) (0)
A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. (2016) (0)
Breast cancer mutation frequency between smokers and non-smokers. (2016) (0)
Breast Cancer Tamoxifen Dose Escalation in Patients With Diminished CYP 2 D 6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (2016) (0)
Somatic cancer variant curation and harmonization through consensus minimum variant level data (2016) (0)
Abstract P5-12-06: Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen (2016) (0)
Using the genome to improve therapeutics Werner Kalow Urs A (2001) (0)
Carvedilol Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (0)
Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics (2014) (0)
modest clinical significance, and moreover will require validation in another independent data set. (2011) (0)
Abstract 2992: Propranolol induces G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway (2016) (0)
β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer (2021) (0)
Differentially expressed genes in human peripheral blood as potential markers for statin response (2011) (0)
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. (2011) (0)
Untapped resources for pharmacogenomic discovery in psychiatry. (2008) (0)
Erratum: Abstract OIII-B-1: Genetic markers associated with platinum/taxanes-induced gastrointestinal toxicity in SCOTROC1 Trial (Clinical Pharmacology and Therapeutics (2011) 89 (S66) DOI:10.1038/clpt.2010.334) (2011) (0)
Lesinurad Therapy and CYP2C9 Genotype -- Medical Genetics Summaries (2012) (0)
Susceptibility to Alkylator-Induced Cancer Is a Heritable Trait. (2005) (0)
Pharmacogenomics of Colorectal Cancer (2006) (0)
Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics (2014) (0)
Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study. (2004) (0)
Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial (Preprint) (2020) (0)
1142-180 Peroxisome proliferator-activated receptor-alpha intron 7 polymorphism exhibits racial dimorphism and is associated with increased left ventricular mass (2004) (0)
Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) (2014) (0)
Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase (2000) (0)
Gentamicin Therapy and MT-RNR1 Genotype -- Medical Genetics Summaries (2012) (0)
Clinical Pharmacodynamics of Anticancer Drugs (2019) (0)
Brivaracetam Therapy and CYP2C19 Genotype -- Medical Genetics Summaries (2012) (0)
OP-JNCI190013 531..537 (2019) (0)
Pediatric Pharmacokinetics and Therapeutic Drug Monitoring (1992) (0)
Drugs in the postgenomic era (2001) (0)
Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms (2014) (0)
Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics 1 (2003) (0)
Budget Impact Analysis of CYP2C19 Genotyping to Target Voriconazole Prophylaxis During Induction-Consolidation Therapy in Acute Myeloid Leukemia (AML) in The United States. (2014) (0)
methods software for association mapping in dose-response genome-wide association studies. (2013) (0)
University of Dundee Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes Rotroff, (2018) (0)
Abstract P2-03-08: Influence of mutagen exposure on molecular profile in breast cancer (2017) (0)
Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer. (2020) (0)
D3-02: Updated Paclitaxel-Carboplatin Pharmacogenomic (PG) Analysis of Japan-SWOG Common Arm Study in Advanced Non-Small Cell Lung Cancer (NSCLC) (2007) (0)
Clinical pharmacologyPharmacokinetics for the prescriber (2012) (0)
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
The pan-cancer, pan-biomarker landscape for precision immuno-oncology. (2017) (0)
Risperidone Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (0)
Biweekly oxaliplatin with gemcitabine and capecitabine in advanced gastrointestinal malignancies: A phase I study (2007) (0)
Final results of the UGT1A1-based dose modification of irinotecan and its impact on rates of severe neutropenia and hospitalization. (2014) (0)
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). (2014) (0)
Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) (2016) (0)
Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials. (2013) (0)
Abstract 1409: Is it what's on the inside that counts? Melanoma mutation profiling and outcomes with immunotherapy (2016) (0)
When will clinical trials finally reflect diversity? (2018) (0)
Genomics, proteomics and pharmacogenetics - Therapeutic approaches (2005) (0)
Pharmacogenetics and Pharmacogenomics (2013) (0)
State-of-the-Art Lecture: A gene expression signature to predict recurrence of Dukes’ B colon cancer (2006) (0)
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. (2018) (0)
Why do we need another journal of pharmacogenomics research and personalized medicine? (2021) (0)
KRAS mutation as a prognostic factor in patients undergoing hepatic resection for metastatic colorectal cancer. (2012) (0)
Lacosamide Therapy and CYP2C19 Genotype -- Medical Genetics Summaries (2012) (0)
Molecular therapeutics: are we making progress? (2003) (0)
Correction: Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial (2021) (0)
S1.4 - Personalised treatment of cancer (2020) (0)
Prognostic Markers in Colon Cancer (2013) (0)
A clinician's guide to the polmerase chain reaction (2000) (0)
Taxane-platinum pharmacogenomic predictors of outcome in Japan-USA common arm studies in advanced non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics: M08-01 (2007) (0)
Abstract 4567: Immunoclassification of gastric cancer in the context of clinical outcome (2017) (0)
Phase I and Pharmacology Studies (2004) (0)
ABO Blood Group -- Medical Genetics Summaries (2012) (0)
Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response (2008) (0)
As the science of genomics has matured , it is increasingly seen as a tool used in clinical practice to design new treatments and to tailor current treatments more effectively (2008) (0)
Ethnic considerations in pharmacogenetic studies - In reply (2008) (0)
Pharmacogenomics: Success and Challenges (2018) (0)
A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC) (2005) (0)
Incidence and average cost per toxicity in patients treated with nivolumab. (2017) (0)
Abstract 3691: Genetic Polymorphisms in the ACE Gene and the GJA4 Gene Modify ACE-inhibitor Efficacy in Post-ACS Patients (2006) (0)
Abstract 3190: Mortality in Diabetic Acute Coronary Syndrome Patients is Associated with a Novel Variant in the PPAR alpha Gene Promoter that Confers Differential ERR Binding (2006) (0)
McCune-Albright Syndrome -- Medical Genetics Summaries (2012) (0)
Abstract 3692: PPARA Genotype is Associated with Differential Response to Beta-Blocker Therapy in Patients Following Acute Coronary Syndromes (2006) (0)
The landscape for genetic eligibility to basket clinical trials. (2015) (0)
ヒトCYP2A6新規変異型、CYP2A6*1F、CYP2A6*1Gの解析 (2004) (0)
Abstract 4304: Prevalence and triggers of drug-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a cancer patient cohort (2016) (0)
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer (2019) (0)
Pathophysiology and drug targets in metastatic colorectal cancer (2011) (0)
Genetic variation determines VEGF-A plasma levels in cancer patients (2018) (0)
Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH). (2005) (0)
Abstract 904: A Comparative Genomics Approach Identifies A Polymorphism In Calumenin As A Predictor Of High Warfarin Dose In African American Patients. (2007) (0)
Correction: Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial (Preprint) (2021) (0)
Evaluating variability in fluorouracil (FU) exposure in obese and non-obese patients with colorectal cancer using full weight-based dosing. (2013) (0)
Irinotecan Pharmacogenetics: Is It Time (2004) (0)
Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance (2016) (0)
Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model (2021) (0)
Oxaliplatin toxicity: preliminary evaluation in inbred mouse (2006) (0)
Budget impact analysis of CYP2C19 genotyping to guide voriconazole prophylaxis in acute myeloid leukemia (AML). (2015) (0)
&bgr;2-Adrenergic Receptor Genotype Predicts Survival: Implications and Future Directions (2006) (0)
Genomics, proteomics and pharmacogenetics - Experimental approaches (2005) (0)
The Radiosensitivity Index (RSI) and the Connectivity Map: A Genomically Guided Approach for the Identification of Novel Radiosensitizers (2016) (0)
Vemurafenib Therapy and BRAF and NRAS Genotype -- Medical Genetics Summaries (2012) (0)
A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma (2022) (0)
, 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy A Community-Based Multicenter Trial of Pharmacokinetically Guided (2014) (0)
CYP2C19-guided voriconazole prophylaxis in neutropenic AML patients. (2018) (0)
Venlafaxine Therapy and CYP2D6 Genotype -- Medical Genetics Summaries (2012) (0)
Unfavorable expression of pharmacologic markers in mucinous colorectal cancer (CRC) (2004) (0)
The Development of an Infrastructure to Facilitate the Use of Whole Genome Sequencing for Population Health (2022) (0)
Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology. (2018) (0)
Candidate gene selection in pharmacogenomics: biology leads the way. (2004) (0)
Pan-cancer opportunities for off-label immunotherapy based on nonsynonymous mutation burden. (2017) (0)
Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. (2020) (0)
2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 (2015) (0)
Abstract 1186: Propranolol could overcome BRAF inhibitors resistance by multiple mechanisms in melanoma (2017) (0)
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly (2016) (0)
Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy. (2018) (0)
Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Howard Lewis Mcleod?

Howard Lewis Mcleod is affiliated with the following schools:

Central South University

Howard Lewis Mcleod's Academic­Influence.com Rankings

Why Is Howard Lewis Mcleod Influential?

Howard Lewis Mcleod's Published Works

Published Works

What Schools Are Affiliated With Howard Lewis Mcleod?

Howard Lewis Mcleod's AcademicInfluence.com Rankings